This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gondek, K. Articles by Woolley, J. M. Search for Related Content PubMed PubMed Citation Articles by Gondek, K. Articles by Woolley, J. M.

Current Status of Patient-Reported Outcomes in Industry-Sponsored Oncology Clinical Trials and Product Labels

Kathleen Gondek, Pierre-Philippe Sagnier, Kim Gilchrist, J. Michael Woolley

From the Bayer Corporation, West Haven, CT; AstraZeneca Pharmaceuticals, Wilmington, DE; Amgen Inc, Thousand Oaks, CA; and Bayer Pharmaceuticals, Puteaux, France

Address reprint requests to Kathleen Gondek, PhD, Bayer Corporation, 400 Morgan Lane, West Haven, CT 06516; e-mail: kathleen.gondek{at}bayer.com

Assessing patient-reported outcomes (PROs) in clinical trials is of interest to clinicians, patients, regulators, and industry. The use and impact of PROs is a growing area of methodologic research, particularly as they relate to tumor types, biomarkers, and various patient populations and cultures. Both the US Food and Drug Administration (FDA) and European Agency for the Evaluation of Medicinal Products in recent guidance have acknowledged the need to account for treatment-related impact on patient symptoms and/or health-related quality of life (HRQOL). Clinical research likely reflects the informative value of PROs. A search of www.clinicaltrials.gov, the FDA Web site, and product package inserts was conducted to assess the inclusion of symptom assessment and HRQOL within industry-sponsored clinical trials in cancer and approved cancer therapies and their respective product labels. Overall, there were 2,704 industry-sponsored oncology trials, of which 322 (12%) included a PRO measure. Of the 70 FDA new or revised labels, only six package inserts include PRO data. Symptoms were assessed uniformly across the phases of clinical trials, whereas HRQOL assessment increased in the later phases of clinical trials. Collecting PRO data can enhance our understanding of cancer burden and the impact of interventions on patients' lives.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				J. Lipscomb, B. B. Reeve, S. B. Clauser, J. S. Abrams, D. Watkins Bruner, L. B. Burke, A. M. Denicoff, P. A. Ganz, K. Gondek, L. M. Minasian, et al. Patient-Reported Outcomes Assessment in Cancer Trials: Taking Stock, Moving Forward J. Clin. Oncol., November 10, 2007; 25(32): 5133 - 5140. [Abstract] [Full Text] [PDF]